Companies › EMS
6 active drug programs in 6 registered trials: 6 Phase 3; Metabolic and endocrine, Immunology, Genitourinary, Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CDE100 association | – | Phase 3 | Primary Dysmenorrhea | Jan 2027 |
| MADALENA ASSOCIATION | – | Phase 3 | Type 2 Diabetes Mellitus | Jun 2027 |
| BERLIM 25/20 ASSOCIATION SGLT2 inhibitor (empagliflozin 25 mg) combined with HMG-CoA reductase inhibitor (rosuvasta | SGLT2, LDLR | Phase 3 | Dyslipidemia Associated With Type II Diabetes Mellitus | Sep 2027 |
| Finlândia Association | – | Phase 3 | Androgenetic Alopecia | Sep 2027 |
| Piemonte association unclear - multi-component drug association for type 2 diabetes | – | Phase 3 | Type II Diabetes | Sep 2027 |
| Praga formulation Voltage-gated calcium channel modulator | – | Phase 3 | Neuropathic Pain | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04666714 | Praga formulation | Phase 3 | Neuropathic Pain | Neurology | Sep 2025 |
| NCT05640232 | CDE100 association | Phase 3 | Primary Dysmenorrhea | Genitourinary | Jan 2027 |
| NCT04670666 | MADALENA ASSOCIATION | Phase 3 | Type 2 Diabetes Mellitus | Metabolic and endocrine | Jun 2027 |
| NCT04594018 | Finlândia Association | Phase 3 | Androgenetic Alopecia | Immunology | Sep 2027 |
| NCT04602754 | BERLIM 25/20 ASSOCIATION | Phase 3 | Dyslipidemia Associated With Type II Diabetes Mellitus | Metabolic and endocrine | Sep 2027 |
| NCT05028140 | Piemonte association | Phase 3 | Type II Diabetes | Metabolic and endocrine | Sep 2027 |
Gan & Lee Pharmaceuticals. Fresenius Kabi Renibus Therapeutics Azafaros Kowa Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.